Intended for healthcare professionals

Letters HPV quadrivalent vaccine

Authors’ reply to Fiala

BMJ 2012; 344 doi: (Published 08 May 2012) Cite this as: BMJ 2012;344:e3198
  1. Elmar A Joura, associate professor1,
  2. Heather L Sings, director, global scientific and medical publications2,
  3. Richard M Haupt, executive director, clinical research2
  1. 1Department of Gynaecology and Obstetrics, Medical University of Vienna, Comprehensive Cancer Centre, A-1090 Vienna, Austria
  2. 2Merck Sharp and Dohme, Whitehouse Station, NJ, USA
  1. elmar.joura{at}

The findings in table 3 are not unexpected.1 2 As Brown and colleagues reported,3 and we stated in our paper,2 the FUTURE I and II clinical trials showed that vaccination reduced the incidence of cervical intraepithelial neoplasia grade 3 or worse associated with 10 non-vaccine human papillomavirus (HPV) types by 32.5% (95% CI 6.0% to 51.9%). The analyses in table …

View Full Text

Log in

Log in through your institution


* For online subscription